Open AccessP665: CARDIAC ADVERSE EVENTS AND SECOND PRIMARY MALIGNANCIES WITH ACALABRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA ‐A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Author(s) -
Parmar K.,
Pawar D.,
Bharathidasan K.,
DelRioPertuz G.,
Tijani L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845544.26496.3f
Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , chlorambucil , adverse effect , obinutuzumab , oncology , ofatumumab , bendamustine , randomized controlled trial , discontinuation , leukemia , chemotherapy , cyclophosphamide